甲状腺功能测试的变化和高甲状腺症中心血管疾病的发生率
Nelli Suonsyrjä1, Iina Laihia1, Heini Huhtala2
1Department of Internal Medicine, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
在抗甲状腺药物治疗期间,甲状腺功能测试的变化,特别是自由甲状腺素 (fT4) 水平,与心血管风险增加有关. 这种关联甚至在具有阳性铁红素受体抗体 (TRAbs) 的患者中仍然存在.
科学领域:
- 内分泌学 在内分泌学.
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在抗甲状腺药物 (ATD) 治疗期间甲状腺功能测试 (TFT) 的变化在不良健康结果方面没有得到充分研究.
- 在接受ATD治疗的甲状腺功能增强症患者中,心血管病率是一个重大问题.
研究的目的:
- 调查治疗ATD的患者中TFT变异性和心血管发病率之间的关联.
- 在ATD治疗期间确定特定的TFT参数和影响心血管风险的临床因素.
主要方法:
- 对394名甲状腺过高患者进行了回顾性队列研究,这些患者接受了ATD治疗.
- 计算后续TSH,ft4和ft3测量的变化系数 (CVs).
- 后勤回归分析以评估TFT变异性,基线因素和与心血管疾病相关的医院访问之间的关联.
主要成果:
- 增加fT4变异性 (fT4-CV) 是心血管疾病的独立风险因素 (OR:1.02,95% CI:1.01-1.04).
- 年龄和男性性别也增加了心血管风险,而阳性TRAbs显示有保护作用 (OR:0.29,95%CI:0.14-0.61).
- 即使在阳性TRAbs.患者中,fT4变异仍然与心血管疾病相关.
结论:
- 在ATD治疗期间fT4水平的变化与心血管疾病发病率的增加有关.
- fT4变异性与心血管风险之间的关联不管TRAb状态如何,都存在.
更多相关视频
08:13In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography
Published on: February 16, 2016
07:51Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
相关概念视频
Variability: Analysis
The range is a simple measure of variability, indicating the difference between the highest and...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Coronary Artery Disease III: Clinical Manifestations
Coronary Artery Disease II: Pathophysiology
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
